TY - JOUR
T1 - Report of the 6th International Workshop on PET in lymphoma
AU - Nanni, Cristina
AU - Cottereau, Anne Ségolène
AU - Lopci, Egesta
AU - Bodet-Milin, Caroline
AU - Coronado, Monica
AU - Pro, Barbara
AU - Kim, Wong Seog
AU - Trotman, Judith
AU - Barrington, Sally
AU - Duhrsen, Ulrich
AU - Vander Borght, Thierry
AU - Zamagni, Elena
AU - Kraeber-Bodéré, Françoise
AU - Messiou, Christina
AU - Rahmouni, Alain
AU - Buvat, Irène
AU - Andre, Marc
AU - Hertzberg, Mark
AU - Oyen, Wim
AU - Casasnovas, Olivier
AU - Luminari, Stefano
AU - Garderet, Laurent
AU - Montravers, Françoise
AU - Kobe, Carsten
AU - Kluge, Regine
AU - Versari, Annibale
AU - Zucca, Emanuele
AU - Moreau, Philippe
AU - Cheson, Bruce
AU - Haioun, Corinne
AU - Gallamini, Andrea
AU - Meignan, Michel
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/10/3
Y1 - 2017/10/3
N2 - Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented. For the first time, specialists in the field of multiple myeloma (MM) were involved in the expert session. The aim was to establish from the experience of Italian and French studies new guidelines of FDG-PET/CT reporting for myeloma staging and restaging. The meeting dedicated an entire session to MM imaging followed by a session on the role of PET in Peripheral T cell Lymphoma. An entire session addressed the issues of Deauville scale particularly for end treatment assessment and the challenging consequences of immunomodulatory treatments on PET reporting. A specific session presented the potential role of baseline metabolic tumor measurement to predict outcome and identify different risk categories and the main results obtained in different lymphoma entities were described. Whether it could replace clinical staging has been extensively discussed. The more recent results obtained in the H10 trial have been presented and compared to the published data in early stage Hodgkin lymphoma. Finally, the ongoing studies using PET for guiding therapeutic strategies have been reported by the various lymphoma cooperative groups that participated to the meeting.
AB - Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented. For the first time, specialists in the field of multiple myeloma (MM) were involved in the expert session. The aim was to establish from the experience of Italian and French studies new guidelines of FDG-PET/CT reporting for myeloma staging and restaging. The meeting dedicated an entire session to MM imaging followed by a session on the role of PET in Peripheral T cell Lymphoma. An entire session addressed the issues of Deauville scale particularly for end treatment assessment and the challenging consequences of immunomodulatory treatments on PET reporting. A specific session presented the potential role of baseline metabolic tumor measurement to predict outcome and identify different risk categories and the main results obtained in different lymphoma entities were described. Whether it could replace clinical staging has been extensively discussed. The more recent results obtained in the H10 trial have been presented and compared to the published data in early stage Hodgkin lymphoma. Finally, the ongoing studies using PET for guiding therapeutic strategies have been reported by the various lymphoma cooperative groups that participated to the meeting.
KW - PET
KW - lymphoma
KW - myeloma
UR - http://www.scopus.com/inward/record.url?scp=85014580423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014580423&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1298752
DO - 10.1080/10428194.2017.1298752
M3 - Article
C2 - 28264597
AN - SCOPUS:85014580423
SN - 1042-8194
VL - 58
SP - 2298
EP - 2303
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -
